David Yi

Norton Rose Fulbright Canada LLP

Related services and key industries


David Yi is a member of the intellectual property group. He practises in all aspects of intellectual property law with an emphasis on complex patent litigation including patent infringement and validity matters and proceedings under section 6 of the Patented Medicines (Notice of Compliance) Regulations. Mr. Yi has particular experience in damages matters, including actions for patent infringement damages and actions under section 8 of the Patented Medicines (Notice of Compliance) Regulations.

Mr. Yi's clients span a variety of industries, including the life sciences and healthcare, and technology spaces. He has experience in matters before the Federal Court, Federal Court of Appeal, and Ontario Superior Court. Mr. Yi's practice also assists clients in navigating matters where antitrust and competition issues intersect with intellectual property disputes.

Before joining us, he completed a clerkship at the Federal Court with the Honourable Mr. Justice Zinn. Prior to that, he was a summer and articling student at a national law firm in Toronto.

Mr. Yi has participated in, and continues to coach law students, in a variety of advocacy competitions, including the Harold G. Fox Intellectual Property Moot. He volunteers for duty counsel shifts with Pro Bono Law Ontario's legal clinics, an extension of his commitment to improving access to quality pro bono legal services from law school where he was the director of the Pro Bono Students Canada Wills Clinic.

Professional experience

Expand all Collapse all

J.D., University of Toronto, 2012

B.H.Sc.(Hons.), McMaster University, 2009

  • Ontario 2013

Mr. Yi has acted in the following matters:

  • Co-counsel on a patent infringement/impeachment action relating to automotive products.
  • Represented defendant in successfully obtaining summary dismissal of claims under the Ontario and UK Statute of Monopolies.
  • Represented defendants in eight different actions for damages brought under section 8 of the Patented Medicines (Notice of Compliance) Regulations.
  • Represented defendant in a patent impeachment action related to drugs for treating anemia.
  • Represented patentee on applications brought under the Patented Medicines (Notice of Compliance) Regulations in connection with a patented invention for a drug used for preventing and treating osteoporosis.
  • IAM Patent 1000, Recommended Individual: Litigation, Law Business Research Ltd., 2024 
  • Managing IP, IP Stars, 2023: Notable Practitioner
  • Copyright protection for AI-created work? IP monitor, March 21, 2022
  • AI inventorship on the horizon: DABUS comes to Canada, February 9, 2022.
  • Pharma in Brief: The 2021 Year in Review, January 9, 2022.
  • AI Inventorship on the Horizon: November 4, 2021 (Part 3) | October 29, 2021 (Part 2) | October 14, 2021 (Part 1).
  • AI and Drug Discovery, Part 3: Protecting the Value of Data in Collaborations, September 23, 2019 (Part 3) | September 16, 2019 (Part 2) | September 9, 2019 (Part 1)
  • AI and Drug Discovery, Part 2: In-Depth Look at the Mellody Project, September 16, 2019 (Part 2) | September 23, 2019 (Part 3) | September 9, 2019 (Part 1)
  • AI and Drug Discovery, Part 1: Collaborations Between Pharma and AI, September 9, 2019 (Part 1) | September 16, 2019 (Part 2) | September 23, 2019 (Part 3)
  • Derailed on obviousness: Court of Appeal reminds us the characteristics of the skilled worker and common general knowledge are key, August 8, 2019.
  • AI and drug development:  The current landscape and IP considerations, May 8, 2018.
  • Canadian Bar Association
  • Ontario Bar Association
  • Toronto Intellectual Property Group